PMID- 15197782
OWN - NLM
STAT- MEDLINE
DCOM- 20040805
LR  - 20160303
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 111
IP  - 2
DP  - 2004 Aug 20
TI  - Differential expression of 9-O-acetylated sialoglycoconjugates on leukemic 
      blasts: a potential tool for long-term monitoring of children with acute 
      lymphoblastic leukemia.
PG  - 270-7
AB  - Earlier studies have demonstrated overexpression of 9-O-acetylated 
      sialoglycoconjugates (9-O-AcSGs) on lymphoblasts, concomitant with high titers of 
      anti-9-O-AcSG antibodies in childhood acute lymphoblastic leukemia (ALL). Our aim 
      was to evaluate the correlation between expression of different 9-O-AcSGs during 
      chemotherapeutic treatment. Accordingly, expression of 9-O-AcSGs on lymphoblasts 
      of ALL patients (n = 70) were longitudinally monitored for 6 years (1997-2002), 
      using Achatinin-H, a 9-O-acetylated sialic acid (9-O-AcSA) binding lectin with 
      preferential affinity for 9-O-AcSGs with terminal 9-O-AcSA alpha 2-->6GalNAc. 
      Western blot analysis of patients (n = 30) showed that 3 ALL-specific 9-O-AcSGs 
      (90, 120 and 135 kDa) were induced at presentation; all these bands disappeared 
      after treatment in patients (n = 22) who had disease-free survival. The 90 kDa 
      band persisted in 8 patients who subsequently relapsed with reexpression of the 
      120 kDa band. FACS analysis revealed that at presentation (n = 70) 90.1 +/- 5.0% 
      cells expressed 9-O-AcSGs, which decreased progressively with chemotherapy, 
      remained <5% during clinical remission and reappeared in relapse (80 +/- 10%, n = 
      18). Early clearance of 9-O-AcSG(+) cells, during 4-8 weeks of treatment showed a 
      good correlation with low risk of relapse. Sensitivity of detection of 
      9-O-AcSG(+) cells was 0.1%. Numbers of both high- and low-affinity binding sites 
      were maximum at presentation, decreased with treatment and increased again in 
      clinical relapse. We propose that close monitoring of 90 and 120 kDa 9-O-AcSGs 
      may serve as a reliable index for long-term management of childhood ALL and 
      merits therapeutic consideration.
CI  - Copyright 2004 Wiley-Liss, Inc.
FAU - Pal, Santanu
AU  - Pal S
AD  - Immunobiology Division, Indian Institute of Chemical Biology, Kolkata, India.
FAU - Ghosh, Shyamasree
AU  - Ghosh S
FAU - Bandyopadhyay, Suman
AU  - Bandyopadhyay S
FAU - Mandal, Chhabinath
AU  - Mandal C
FAU - Bandhyopadhyay, Santu
AU  - Bandhyopadhyay S
FAU - Kumar Bhattacharya, Dilip
AU  - Kumar Bhattacharya D
FAU - Mandal, Chitra
AU  - Mandal C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Glycoconjugates)
RN  - 0 (Sialic Acids)
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Blotting, Western
MH  - Child
MH  - Child, Preschool
MH  - Disease-Free Survival
MH  - Female
MH  - *Gene Expression Profiling
MH  - Glycoconjugates/*biosynthesis
MH  - Humans
MH  - Infant
MH  - Male
MH  - Neoplasm, Residual
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/*genetics/pathology
MH  - Prognosis
MH  - Recurrence
MH  - Sialic Acids/*biosynthesis
MH  - Treatment Outcome
EDAT- 2004/06/16 05:00
MHDA- 2004/08/06 05:00
CRDT- 2004/06/16 05:00
PHST- 2004/06/16 05:00 [pubmed]
PHST- 2004/08/06 05:00 [medline]
PHST- 2004/06/16 05:00 [entrez]
AID - 10.1002/ijc.20246 [doi]
PST - ppublish
SO  - Int J Cancer. 2004 Aug 20;111(2):270-7. doi: 10.1002/ijc.20246.